Table 2

Demographic and clinical characteristics of study participants
PD (n = 65) Control (n = 27)
Male/female (n) 48/17 19/8
Age (years) 66.2 ± 9.4 68.7 ± 9.6
Education (years) 12.8 ± 2.9 13.4 ± 2.9
MMSE 28.0 ± 2.7 29.0 ± 1.1
MoCA 23.9 ± 5.1 27.0 ± 1.9
Symptom duration (years) 6.3 ± 5.7
range 0.5-30
UPDRS part III 33.7 ± 16.3 -
Modified H & Y stage (median) 2.5
range 1–4
Cognitive status (n)
    Unimpaired 41 27
    MCI 14
    Dementia 10
PD Medication Status (n)
  No medication 24
  On Medication 41
    LED (mg/day) 572.4 ± 339.5

Values are expressed as mean ± standard deviation, unless otherwise stated. MMSE Mini Mental State Examination, MoCA Montreal Cognitive Assessment, UPDRS Unified Parkinson’s Disease Rating Scale, H & Y Hoehn and Yahr scale, MCI mild cognitive impairment, LED levodopa equivalent dose.

Pitcher et al.

Pitcher et al. Translational Neurodegeneration 2012 1:17   doi:10.1186/2047-9158-1-17

Open Data